Clinical Overview > Condition/ Syndrome > Paraganglioma
You are looking at 1 - 7 of 7 items
Search for other papers by M Majumder in
Google Scholar
PubMed
Cancer Genetics Laboratory, Kolling Institute of Medical Research, New South Wales, Sydney, Australia
Faculty of Medicine and Health, University of Sydney, New South Wales, Sydney, Australia
Search for other papers by M L Gild in
Google Scholar
PubMed
Cancer Genetics Laboratory, Kolling Institute of Medical Research, New South Wales, Sydney, Australia
Faculty of Medicine and Health, University of Sydney, New South Wales, Sydney, Australia
Search for other papers by B G Robinson in
Google Scholar
PubMed
Summary
Pregnancy in the setting of metastatic paraganglioma is challenging, particularly in the context of tyrosine kinase use. We describe a 26-year-old female with a background of metastatic paraganglioma harboring a pathogenic SDHB variant, requiring sunitinib, which was withheld to facilitate the safe conception and delivery of a healthy baby. She required no alpha- or beta-blockade during her pregnancy and exhibited no signs of tumor progression or symptoms throughout this period. Historically, higher rates of fetal and maternal morbidity and mortality have been experienced in the setting of pregnancy. Although limited data exist on the management of metastatic paraganglioma in pregnant patients, this case suggests that careful treatment modifications, such as temporary tyrosine kinase therapy cessation and vigilant monitoring, can result in successful pregnancies without compromising maternal or fetal well-being.
Learning points
-
Paraganglioma in pregnancy has been associated with poor fetal and maternal morbidity and mortality.
-
Many of the treatment modalities for metastatic paraganglioma, including tyrosine kinase inhibitors, can affect fertility or cannot be utilized in pregnancy, necessitating the temporary suspension of these treatments.
-
This case exemplifies that careful clinical and biochemical monitoring during pregnancy is required to avoid maternal and fetal harm while balancing the risk of disease progression off treatment.
Faculty of Medicine of Universidade do Porto, Porto, Portugal
Search for other papers by J Pedro in
Google Scholar
PubMed
Search for other papers by F M Cunha in
Google Scholar
PubMed
Search for other papers by V Neto in
Google Scholar
PubMed
Department of Pneumology, Centro Hospitalar Universitário de São João, Porto, Portugal
Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
Search for other papers by V Hespanhol in
Google Scholar
PubMed
Department of Pathology, Centro Hospitalar Universitário de São João, Porto, Portugal
Search for other papers by D F Martins in
Google Scholar
PubMed
Search for other papers by S Guimarães in
Google Scholar
PubMed
Faculty of Medicine of Universidade do Porto, Porto, Portugal
Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
Search for other papers by A Varela in
Google Scholar
PubMed
Faculty of Medicine of Universidade do Porto, Porto, Portugal
Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
Search for other papers by D Carvalho in
Google Scholar
PubMed
Summary
We describe the case of a 56 year-old woman with the almost simultaneous appearance of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) and a carotid body paraganglioma. Of interest, 6 years earlier, the patient underwent total thyroidectomy due to papillary thyroid carcinoma and, in the meantime, she was submitted to mastectomy to treat an invasive ductal carcinoma of the breast. In order to explain these lesions, an extensive genetic study was performed. Results showed positivity for the presence of the tumor suppressor gene PALB2, whose presence had already been detected in a niece with breast cancer. The patient underwent different procedures to treat the lesions and currently she is symptom-free over 2 years of follow-up.
Learning points:
-
The presence of two rare neoplasms in a single person should raise the suspicion of a common etiology.
-
To the best of our knowledge, this is the first case that shows the coexistence of DIPNECH and paraganglioma.
-
The contribution of the PALB2 gene in the etiology of these rare neoplasms is a possibility.
Search for other papers by Gemma White in
Google Scholar
PubMed
Search for other papers by Nicola Tufton in
Google Scholar
PubMed
Search for other papers by Scott A Akker in
Google Scholar
PubMed
Summary
At least 40% of phaeochromocytomas and paraganglioma’s (PPGLs) are associated with an underlying genetic mutation. The understanding of the genetic landscape of these tumours has rapidly evolved, with 18 associated genes now identified. Among these, mutations in the subunits of succinate dehydrogenase complex (SDH) are the most common, causing around half of familial PPGL cases. Occurrence of PPGLs in carriers of SDHB, SDHC and SDHD subunit mutations has been long reported, but it is only recently that variants in the SDHA subunit have been linked to PPGL formation. Previously documented cases have, to our knowledge, only been found in isolated cases where pathogenic SDHA variants were identified retrospectively. We report the case of an asymptomatic suspected carotid body tumour found during surveillance screening in a 72-year-old female who is a known carrier of a germline SDHA pathogenic variant. To our knowledge, this is the first screen that detected PPGL found in a previously identified SDHA pathogenic variant carrier, during surveillance imaging. This finding supports the use of cascade genetic testing and surveillance screening in all carriers of a pathogenic SDHA variant.
Learning points:
-
SDH mutations are important causes of PPGL disease.
-
SDHA is much rarer compared to SDHB and SDHD mutations.
-
Pathogenicity and penetrance are yet to be fully determined in cases of SDHA-related PPGL.
-
Surveillance screening should be used for SDHA PPGL cases to identify recurrence, metastasis or metachronous disease.
-
Surveillance screening for SDH-related disease should be performed in identified carriers of a pathogenic SDHA variant.
Search for other papers by Ana Gonçalves Ferreira in
Google Scholar
PubMed
Search for other papers by Tiago Nunes da Silva in
Google Scholar
PubMed
Search for other papers by Sofia Alegria in
Google Scholar
PubMed
Search for other papers by Maria Carlos Cordeiro in
Google Scholar
PubMed
Search for other papers by Jorge Portugal in
Google Scholar
PubMed
Summary
Pheochromocytoma/paraganglioma (PPGL) are neuroendocrine tumors that can secrete catecholamines. The authors describe a challenging case who presented as stress cardiomyopathy and myocardial infarction (MI). A 76-year-old man, with a medical history of Parkinson’s disease, type 2 diabetes mellitus, hypertension, dyslipidaemia and a previous inferior MI in 2001, presented to the emergency department due to chest pain, headaches and vomiting. He also reported worsening blood glucose levels and increasing constipation over the preceding weeks. BP was 185/89 mmHg (no other relevant findings). EKG had ST segment depression in leads V2-V6, T troponin was 600 ng/L (<14) and the echocardiogram showed left ventricular hypokinesia with mildly compromised systolic function. Nevertheless, he rapidly progressed to severe biventricular dysfunction. Coronary angiogram showed a 90% anterior descendent coronary artery occlusion (already present in 2001), which was treated with angioplasty/stenting. In the following days, a very labile BP profile and unexplained sinus tachycardia episodes were observed. Because of sustained severe constipation, the patient underwent an abdominal CT that revealed a retroperitoneal, heterogeneous, hypervascular mass on the right (62 × 35 mm), most likely a paraganglioma. Urinary metanephrines were increased several fold. 68Ga-DOTANOC PET-CT scan showed increased uptake in the abdominal mass (no evidence of disease elsewhere). He was started on a calcium-channel blocker and alpha blockade and underwent surgery with no major complications. Eight months after surgery, the patient has no evidence of disease. Genetic testing was negative for known germline mutations. This was a challenging diagnosis, but it was essential for adequate cardiovascular stabilization and to reduce further morbidity.
Learning points:
-
PPGL frequently produces catecholamines and can manifest with several cardiovascular syndromes, including stress cardiomyopathy and myocardial infarction.
-
Even in the presence of coronary artery disease (CAD), PPGL should be suspected if signs or symptoms attributed to catecholamine excess are present (in this case, high blood pressure, worsening hyperglycaemia and constipation).
-
Establishing the correct diagnosis is important for adequate treatment choice.
-
Inodilators and mechanical support might be preferable options (if available) for cardiovascular stabilization prior to alpha blockade and surgery.
-
Laboratory interference should be suspected irrespective of metanephrine levels, especially in the context of treated Parkinson’s disease.
First Surgical Department of General Hospital of Athens ‘Georgios Gennimatas’, Alpha Institute of Biomedical Sciences (AIBS), Department of Pathology, Mesogeion 154, Athens 15669, Greece
Search for other papers by Marinos C Makris in
Google Scholar
PubMed
Search for other papers by Konstantinos C Koumarelas in
Google Scholar
PubMed
Search for other papers by Apostolos S Mitrousias in
Google Scholar
PubMed
Search for other papers by Giannos G Psathas in
Google Scholar
PubMed
Search for other papers by Athanasios Mantzioros in
Google Scholar
PubMed
Search for other papers by Stratigoula P Sakellariou in
Google Scholar
PubMed
Search for other papers by Panagiota Ntailiani in
Google Scholar
PubMed
Search for other papers by Evripides Yettimis in
Google Scholar
PubMed
Summary
Until now, less than ten cases of extra-adrenal chromaffin cell tumors have been reported to be localized to the spermatic cord area. All published studies report benign tumors with a diameter <2–3 cm and no invasion of the testis. In this article, we present one case of a giant malignant paraganglioma in the testis of a patient who had initially been operated for a giant mass in the scrotum. The mass developed in approximately 4 months. This is the first study reporting the following findings: i) paraganglioma was found exclusively in the testis, invading the testicle and not the spermatic cord, ii) it was malignant with lung metastasis, and iii) its size was 17.5 cm×10 cm×9.5 cm. We present the first – giant – malignant paraganglioma. Moreover, it is the first case report of a paraganglioma in the testis.
Learning points
-
This is the first study reporting the following findings:
-
Paraganglioma found exclusively in the testis, invading the testicle and not the spermatic cord.
-
It is malignant with lung metastasis.
-
It is of the size 17.5 cm×10 cm×9.5 cm.
Search for other papers by Omayma Elshafie in
Google Scholar
PubMed
Search for other papers by Yahya Al Badaai in
Google Scholar
PubMed
Search for other papers by Khalifa Alwahaibi in
Google Scholar
PubMed
Search for other papers by Asim Qureshi in
Google Scholar
PubMed
Search for other papers by Samir Hussein in
Google Scholar
PubMed
Search for other papers by Faisal Al Azzri in
Google Scholar
PubMed
Search for other papers by Ali Almamari in
Google Scholar
PubMed
Search for other papers by Nicholas Woodhouse in
Google Scholar
PubMed
Summary
A 48-year-old hypertensive and diabetic patient presented with a 10-year history of progressive right facial pain, tinnitus, hearing loss, sweating, and palpitations. Investigations revealed a 5.6 cm vascular tumor at the carotid bifurcation. Her blood pressure (BP) was 170/110, on lisinopril 20 mg od and amlodipine 10 mg od and 100 U of insulin daily. A catecholamine-secreting carotid body paraganglioma (CSCBP) was suspected; the diagnosis was confirmed biochemically by determining plasma norepinephrine (NE) level, 89 000 pmol/l, and chromogranin A (CgA) level, 279 μg/l. Meta-iodobenzylguanidine and octreotide scanning confirmed a single tumor in the neck. A week after giving the patient a trial of octreotide 100 μg 8 h, the NE level dropped progressively from 50 000 to 25 000 pmol/l and CgA from 279 to 25 μg/l. Treatment was therefore continued with labetalol 200 mg twice daily (bid) and long-acting octreotide-LA initially using 40 mg/month and later increasing to 80 mg/month. On this dose and with a reduced labetalol intake of 100 mg bid, BP was maintained at 130/70 and her symptoms resolved completely. CgA levels returned to normal in the first week and these were maintained throughout the 3 month treatment period. During tumor resection, there were minimal BP fluctuations during the 10 h procedure. We conclude that short-term high-dose octreotide-LA might prove valuable in the preoperative management of catecholamine-secreting tumors. To the best of our knowledge, this is the first report on the successful use of octreotide in a CSCBP.
Learning points
-
The value of octreotide scanning in the localization of extra-adrenal pheochromocytoma.
-
Control of catecholamine secretion using high-dose octreotide.
-
This is a report of a rare cause of secondary diabetes and hypertension.
Search for other papers by F Serra in
Google Scholar
PubMed
Search for other papers by S Duarte in
Google Scholar
PubMed
Search for other papers by S Abreu in
Google Scholar
PubMed
Search for other papers by C Marques in
Google Scholar
PubMed
Search for other papers by J Cassis in
Google Scholar
PubMed
Search for other papers by M Saraiva in
Google Scholar
PubMed
Summary
Ectopic secretion of ACTH is an infrequent cause of Cushing's syndrome. We report a case of ectopic ACTH syndrome caused by a nasal paraganglioma, a 68-year-old female with clinical features of Cushing's syndrome, serious hypokalaemia and a right paranasal sinus' lesion. Cranial magnetic resonance image showed a 46-mm mass on the right paranasal sinuses. Endocrinological investigation confirmed the diagnosis of ectopic ACTH production. Resection of the tumour normalised ACTH and cortisol secretion. The tumour was found to be a paraganglioma through microscopic analysis. On follow-up 3 months later, the patient showed nearly complete clinical recovery. Ectopic ACTH syndrome due to nasal paraganglioma is extremely uncommon, as only two other cases have been discussed in the literature.
Learning points
-
Ectopic Cushing's syndrome accounts for 10% of Cushing's syndrome etiologies.
-
Most paraganglioma of the head and neck are not hormonally active.
-
Nasal paraganglioma, especially ACTH producing, is a very rare tumour.
